A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 23 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
- 12 Oct 2014 Planned End Date changed from 1 Apr 2013 to 1 Apr 2015, as reported by ClinicalTrials.gov.